- Home
- AG vs HRMY Comparison
AG vs HRMY Comparison
Compare AG & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AG
- HRMY
- Stock Information
- Founded
- AG 1979
- HRMY 2017
- Country
- AG Canada
- HRMY United States
- Employees
- AG N/A
- HRMY N/A
- Industry
- AG Precious Metals
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- AG Basic Materials
- HRMY Health Care
- Exchange
- AG Nasdaq
- HRMY Nasdaq
- Market Cap
- AG 2.3B
- HRMY 1.9B
- IPO Year
- AG N/A
- HRMY 2020
- Fundamental
- Price
- AG $6.44
- HRMY $33.23
- Analyst Decision
- AG Buy
- HRMY Buy
- Analyst Count
- AG 2
- HRMY 9
- Target Price
- AG $7.50
- HRMY $47.00
- AVG Volume (30 Days)
- AG 10.6M
- HRMY 1.2M
- Earning Date
- AG 11-07-2024
- HRMY 10-29-2024
- Dividend Yield
- AG 0.28%
- HRMY N/A
- EPS Growth
- AG N/A
- HRMY N/A
- EPS
- AG N/A
- HRMY 2.11
- Revenue
- AG $525,212,999.00
- HRMY $681,879,000.00
- Revenue This Year
- AG N/A
- HRMY $24.63
- Revenue Next Year
- AG $26.61
- HRMY $18.04
- P/E Ratio
- AG N/A
- HRMY $15.69
- Revenue Growth
- AG N/A
- HRMY 25.83
- 52 Week Low
- AG $4.17
- HRMY $28.14
- 52 Week High
- AG $8.44
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- AG 44.81
- HRMY 45.24
- Support Level
- AG $6.11
- HRMY $32.35
- Resistance Level
- AG $6.79
- HRMY $33.66
- Average True Range (ATR)
- AG 0.29
- HRMY 1.20
- MACD
- AG -0.05
- HRMY -0.12
- Stochastic Oscillator
- AG 35.27
- HRMY 20.69
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines, in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine and the La Encantada Silver Mine.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.